Life Sciences News | BioTuesdays by Kilmer Lucas IR

Markets

BTIG cuts Zosano Pharma PT to $2 from $7

BTIG slashed the price target for Zosano Pharma (NASDAQ:ZSAN) to $2 from $7, citing a complete response letter about the NDA for Qtrypta, a transdermal microneedle system form of zolmitriptan in development for acute...

October 22, 2020

Developments

TG Therapeutics gets FDA fast track designation for ublituximab plus umbralisib

TG Therapeutics (NASDAQ:TGTX) received the FDA fast track designation for the ublituximab plus umbralisib for the treatment of chronic lymphocytic leukemia (CLL). Ublituximab is a glycoengineered anti-CD20 monoclonal...

October 21, 2020

Developments

Cidara updates Phase 2 rezafungin data

Cidara Therapeutics (NASDAQ:CDTX) reported new data from its Phase 2 STRIVE trial evaluating once-weekly rezafungin for the treatment of candidemia and invasive candidiasis. The trial demonstrated that rezafungin...

October 21, 2020

Developments

IntelGenx grants Tetra Bio-Pharma additional rights to Adversa mucoadhesive delivery technology

IntelGenx (TSXV:IGX; OTCQB:IGXT) granted cannabinoid-derived drug developer Tetra Bio-Pharma (TSX:TBP) (OTCQB:TBPMF) additional exclusive worldwide rights to IntelGenx’s Adversa mucoadhesive delivery technology. Adversa...

October 20, 2020

Developments

Inventiva odiparcil gets FDA fast track designation for mucopolysaccharidosis

Inventiva’s (PSE:IVA; NASDAQ:IVA) odiparcil received FDA fast track designation for the treatment of mucopolysaccharidosis (MPS) Type VI, a rare progressive genetic disorder. MPS is caused by deficient versions of the...

October 20, 2020

Developments

Aclaris doses first patient in Phase 2a atopic dermatitis trial

Aclaris Therapeutics (NASDAQ:ACRS) dosed the first patient in its Phase 2a trial evaluating ATI-1777 for the treatment of moderate-to-severe atopic dermatitis ATI-1777 is a topical Janus kinase (JAK) 1/3 inhibitor...

October 20, 2020

Developments

Evofem Biosciences enrolls first patient in Phase 3 STD prevention trial

Evofem Biosciences (NASDAQ:EVFM) enrolled the first patient in its Phase 3 trial evaluating EVO100 for the prevention of urogenital chlamydia and gonorrhea in women. The trial, called EVOGUARD, will enroll 1,730 women...

October 20, 2020

Developments

Selecta gets FDA rare pediatric disease designation for methylmalonic acidemia gene therapy

Selecta Biosciences’ (NASDAQ:SELB) MMA-101 received FDA rare pediatric disease designation for the treatment of methylmalonic acidemia (MMA). MMA is caused by a mutation in the methylmalonyl-CoA mutase gene, which...

October 20, 2020

Markets

Stifel starts Orthofix Medical at buy; PT $39

Stifel launched coverage of Orthofix Medical (NASDAQ:OFIX) with a “buy” rating and price target of $39. The stock closed at $34.05 on Oct. 19. Orthofix is focused on providing medical devices, operating through the...

October 19, 2020

Markets

Stifel starts Alphatec at buy; PT $13

Stifel initiated coverage of Alphatec Holdings (NASDAQ:ATEC) with a “buy” rating and $13 price target. The stock closed at $9.88 on Oct. 19. Alphatec engages in design, development, and marketing of spinal fusion...

October 19, 2020

Markets

Stifel starts SeaSpine at buy; PT $22

Stifel launched coverage of SeaSpine Holdings (NASDAQ:SPNE) with a “buy” rating and price target of $22. The stock closed at $14.97 on Oct. 19. “After several years of uneven performance post the 2015 spin-out from...

October 19, 2020

Markets

HCW ups Celldex Therapeutics PT to $25 from $16

H.C Wainwright raised its price target for Celldex Therapeutics (NASDAQ:CLDX) to $25 from $16, citing three differentiated programs that are now in the clinic. The stock closed at $15.76 on Oct. 16. “As we have stated...

October 19, 2020

Subscribe